journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/30232468/roles-of-the-rankl-rank-axis-in-antitumour-immunity-implications-for-therapy
#1
REVIEW
Elizabeth Ahern, Mark J Smyth, William C Dougall, Michele W L Teng
Recognizing that the transformative effects of immunotherapy are currently limited to a minority of patients with cancer, research efforts are increasingly focused on expanding and enhancing clinical responses by combining immunotherapies; the repurposing of existing drugs is an attractive approach, given their well-characterized safety and pharmacokinetic profiles. Receptor activator of nuclear factor-κB (RANK) and the RANK ligand (RANKL) were initially described in the context of T cell-dendritic cell interactions; however, the discovery of an obligate role of RANK signalling in osteoclastogenesis led to the development of the anti-RANKL antibody denosumab for antiresorptive indications, including bone metastases...
September 19, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30218030/precision-risk-based-screening-might-maximize-benefit-and-minimize-harm
#2
Laura J Esserman, Andrea Z LaCroix
No abstract text is available yet for this article.
September 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30218029/erlotinib-effective-in-the-neoadjuvant-setting
#3
Peter Sidaway
No abstract text is available yet for this article.
September 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30218028/immunogenomic-features-of-mcrpc-revealed
#4
Peter Sidaway
No abstract text is available yet for this article.
September 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30218027/pd-1-mrna-predicts-response-to-therapy
#5
Peter Sidaway
No abstract text is available yet for this article.
September 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30206303/progress-in-adjuvant-systemic-therapy-for-breast-cancer
#6
REVIEW
Noam F Pondé, Dimitrios Zardavas, Martine Piccart
The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first adjuvant endocrine therapy and chemotherapy trials, continuous improvements of clinical outcomes have been achieved through intense therapeutic escalation, albeit with increased health-care costs and treatment-related toxicities. In contrast to the advances achieved in surgery or radiotherapy, the identification of the patient subgroups that will derive clinical benefit from therapeutic escalation has proved to be a daunting process hindered by a lack of collaboration between scientific groups and by the pace of drug development...
September 11, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30194438/what-s-new-under-the-sun-for-icis
#7
Diana Romero
No abstract text is available yet for this article.
September 7, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30181661/eliminating-mrd-fda-approval-of-blinatumomab-for-b-all-in-complete-remission
#8
Talal Hilal, Vinay Prasad
No abstract text is available yet for this article.
September 4, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30177684/ctdna-predicts-outcomes-in-dlbcl
#9
Peter Sidaway
No abstract text is available yet for this article.
September 3, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30177683/mesothelioma-risk-genes-revealed
#10
Peter Sidaway
No abstract text is available yet for this article.
September 3, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30177682/embracing-a-new-parp-inhibitor
#11
Diana Romero
No abstract text is available yet for this article.
September 3, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30171205/signatures-impres-and-might-turn-the-tide-in-predicting-responses
#12
David Killock
No abstract text is available yet for this article.
August 31, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30135575/alternative-splicing-in-prostate-cancer
#13
REVIEW
Alec Paschalis, Adam Sharp, Jonathan C Welti, Antje Neeb, Ganesh V Raj, Jun Luo, Stephen R Plymate, Johann S de Bono
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain and remain constitutively active in the absence of circulating androgens, thus promoting cancer cell proliferation. Consequently, AR-Vs have been proposed to contribute not only to resistance to anti-androgen therapies but also to resistance to radiotherapy in patients receiving combination therapy by promoting DNA repair...
August 22, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30127492/economic-sustainability-of-immune-checkpoint-inhibitors-the-looming-threat
#14
Vivek Verma
No abstract text is available yet for this article.
August 20, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30108370/making-the-first-move-in-egfr-driven-or-alk-driven-nsclc-first-generation-or-next-generation-tki
#15
REVIEW
Gonzalo Recondo, Francesco Facchinetti, Ken A Olaussen, Benjamin Besse, Luc Friboulet
The traditional approach to the treatment of patients with advanced-stage non-small-cell lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the sequential administration of therapies (sequential treatment approach), in which patients first receive first-generation tyrosine-kinase inhibitors (TKIs), which are eventually replaced by next-generation TKIs and/or chemotherapy upon disease progression, in a decision optionally guided by tumour molecular profiling. In the past few years, this strategy has been challenged by clinical evidence showing improved progression-free survival, improved intracranial disease control and a generally favourable toxicity profile when next-generation EGFR and ALK TKIs are used in the first-line setting...
August 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30087433/mhc-expression-predicts-response
#16
Peter Sidaway
No abstract text is available yet for this article.
August 7, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30082906/management-guidelines-for-paediatric-patients-receiving-chimeric-antigen-receptor-t-cell-therapy
#17
REVIEW
Kris M Mahadeo, Sajad J Khazal, Hisham Abdel-Azim, Julie C Fitzgerald, Agne Taraseviciute, Catherine M Bollard, Priti Tewari, Christine Duncan, Chani Traube, David McCall, Marie E Steiner, Ira M Cheifetz, Leslie E Lehmann, Rodrigo Mejia, John M Slopis, Rajinder Bajwa, Partow Kebriaei, Paul L Martin, Jerelyn Moffet, Jennifer McArthur, Demetrios Petropoulos, Joan O'Hanlon Curry, Sarah Featherston, Jessica Foglesong, Basirat Shoberu, Alison Gulbis, Maria E Mireles, Lisa Hafemeister, Cathy Nguyen, Neena Kapoor, Katayoun Rezvani, Sattva S Neelapu, Elizabeth J Shpall
In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care...
August 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30065313/benefit-of-nanomedicine-confirmed-in-saml
#18
David Killock
No abstract text is available yet for this article.
July 31, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30061740/immunotherapy-responsive-gastric-cancers-identified
#19
Peter Sidaway
No abstract text is available yet for this article.
July 30, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30061739/molecular-therapies-and-precision-medicine-for-hepatocellular-carcinoma
#20
REVIEW
Josep M Llovet, Robert Montal, Daniela Sia, Richard S Finn
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an annual incidence of 1 million cases. Genomic studies have established the landscape of molecular alterations in HCC; however, the most common mutations are not actionable, and only ~25% of tumours harbour potentially targetable drivers. Despite the fact that surveillance programmes lead to early diagnosis in 40-50% of patients, at a point when potentially curative treatments are applicable, almost half of all patients with HCC ultimately receive systemic therapies...
July 30, 2018: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"